Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

• Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
• Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
• Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
• Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

• Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
• Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
• Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
• Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

• Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
• Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
• Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
• Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Activity Description

The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, many clinical questions arise, including ideal sequencing of agents, role of MRD, management of adverse events, and incorporating emerging data of investigational agents. This activity will provide expert interpretation of recently presented data regarding currently available and emerging therapies for the treatment of patients with relapsed or refractory multiple myeloma.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Moderator

Cristina Gasparetto, MD
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Faculty

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Cristina Gasparetto, MD (Moderator)
Consulting Fees: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Contracted Research: GlaxoSmithKline

Maria-Victoria Mateos, MD, PhD
Honorarium (Lectures): Adaptive Biotechnologies, Amgen, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi, Takeda
Honorarium (Advisory Boards): Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Pfizer Inc., Regeneron, Roche, Sanofi, SeaGen, Takeda

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

Accreditation Statement

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

• Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
• Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
• Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
• Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Activity Description

The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, many clinical questions arise, including ideal sequencing of agents, role of MRD, management of adverse events, and incorporating emerging data of investigational agents. This activity will provide expert interpretation of recently presented data regarding currently available and emerging therapies for the treatment of patients with relapsed or refractory multiple myeloma.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Moderator

Cristina Gasparetto, MD
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Faculty

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Cristina Gasparetto, MD (Moderator)
Consulting Fees: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Contracted Research: GlaxoSmithKline

Maria-Victoria Mateos, MD, PhD
Honorarium (Lectures): Adaptive Biotechnologies, Amgen, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi, Takeda
Honorarium (Advisory Boards): Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Pfizer Inc., Regeneron, Roche, Sanofi, SeaGen, Takeda

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

Accreditation Statement

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

• Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
• Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
• Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

• Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
• Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
• Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with mantle cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

1. Summarize criteria required to accurately diagnose patients with mantle cell lymphoma and identify those most likely to benefit from treatment using prognostic indicators
2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with mantle cell lymphoma
3. Formulate best-practice treatment strategies for patients with mantle cell lymphoma, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of mantle cell lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The therapeutic field for MCL is rapidly expanding with an increasing number of targeted therapies, immunotherapies, and novel combination regimens. It is difficult for community oncologists, who see a limited number of patients with MCL, to keep pace with rapidly evolving treatment paradigms, as well as distinguish among these new and emerging strategies in order to best incorporate them into clinical practice.

As treatment for MCL evolves beyond conventional chemoimmunotherapies and ACST, clinicians will require familiarity with the unique safety considerations associated with targeted agents and immunotherapies in order to optimize clinical outcomes.

In addition, diagnosis of MCL presents a clinical challenge given that a community oncologist may only see a patient with MCL once or twice a year, and those patients may have radically different presentations and clinical behaviors. Clinicians are challenged to incorporate available diagnostic criteria, risk stratification, and prognostic indicators that can be used to personalize therapy decisions for this relatively rare hematologic malignancy.

Faculty

Jonathon B. Cohen, MD, MS
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Medical Director, Infusion Services
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has consulted for:
Loxo, Adaptive, Adicet, Cellectar, Beigene, AstraZeneca, Janssen, Pharmacyclics, Kite

Dr. Cohen has research grants from
Genentech, Novartis, BMS/Celgene, LOXO, LAM, BeiGene, Takeda, BioInvent, AstraZeneca

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc. and Kite Pharma, Inc..

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with mantle cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

1. Summarize criteria required to accurately diagnose patients with mantle cell lymphoma and identify those most likely to benefit from treatment using prognostic indicators
2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with mantle cell lymphoma
3. Formulate best-practice treatment strategies for patients with mantle cell lymphoma, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of mantle cell lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The therapeutic field for MCL is rapidly expanding with an increasing number of targeted therapies, immunotherapies, and novel combination regimens. It is difficult for community oncologists, who see a limited number of patients with MCL, to keep pace with rapidly evolving treatment paradigms, as well as distinguish among these new and emerging strategies in order to best incorporate them into clinical practice.

As treatment for MCL evolves beyond conventional chemoimmunotherapies and ACST, clinicians will require familiarity with the unique safety considerations associated with targeted agents and immunotherapies in order to optimize clinical outcomes.

In addition, diagnosis of MCL presents a clinical challenge given that a community oncologist may only see a patient with MCL once or twice a year, and those patients may have radically different presentations and clinical behaviors. Clinicians are challenged to incorporate available diagnostic criteria, risk stratification, and prognostic indicators that can be used to personalize therapy decisions for this relatively rare hematologic malignancy.

Faculty

Jonathon B. Cohen, MD, MS
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Medical Director, Infusion Services
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has consulted for:
Loxo, Adaptive, Adicet, Cellectar, Beigene, AstraZeneca, Janssen, Pharmacyclics, Kite

Dr. Cohen has research grants from
Genentech, Novartis, BMS/Celgene, LOXO, LAM, BeiGene, Takeda, BioInvent, AstraZeneca

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc. and Kite Pharma, Inc..

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com